SEC Tracker
Get the app

Lantheus Holdings LNTH

Lantheus Holdings reports Q3 2026 results

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Worldwide revenue of $389.9 million in Q3 2026
  2. GAAP fully diluted EPS of $0.33, down from $0.41 in Q3 2025
  3. Adjusted fully diluted EPS of $1.68, up from $1.27 in Q3 2025
  4. FDA approves TAUKLARIFY and BRAVNETSA

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Lantheus Holdings files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2835 and related industry codes: the same peer list as the financial tables.

  1. Adma Biologics ADMA public float $4.2B, Jun 30, 2025
  2. Axsome Therapeutics AXSM public float $4.4B, Jun 30, 2025
  3. Soleno Therapeutics SLNO public float $4.1B, Jun 30, 2025
  4. Halozyme Therapeutics HALO public float $4.5B, Jun 30, 2025
  5. Alkermes ALKS public float $4.7B, Jun 30, 2025